Jingwei Biopharmaceutical Technology

Jingwei Biopharmaceutical is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of next-generation antibody-drug conjugates (ADCs) and bispecific antibodies for oncology. The company leverages a proprietary site-specific conjugation platform to create therapies with improved stability, homogeneity, and therapeutic index compared to traditional ADCs. Its lead candidate, JW-001, is a HER2-targeting ADC currently undergoing clinical evaluation for various solid tumors. Jingwei Biopharmaceutical aims to address unmet medical needs in cancer treatment through its innovative linker-payload technologies and antibody engineering capabilities. The company is supported by prominent venture capital investors and focuses on both best-in-class and first-in-class therapeutic strategies.